RxDoctor Payments Data

Robert Browning, MD

Ophthalmology · Madison, MSNPI 1053809566

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 29.3% of the total.

$3,828in general payments, 2019–2025

Across 76 payments — averaging $50.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sight Sciences, Inc.$1K
  • Glaukos Corporation$560
  • Alcon$325
  • Bausch & Lomb Americas Inc.$285
  • Johnson & Johnson Surgical Vision, Inc.$110
  • plus $315 from 8 others

What the payments were for

  • Food & beverage$3,828100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,828 in reported general payments places this provider in the 70th percentile of 150 ophthalmology providers in Mississippi.

See all ophthalmology providers in Mississippi

Medicare billing

Part B allowed, 2024
$186,581
Medicare patients
372
Services billed
1,766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost72$30,100
Prednisolone Acetate204$6,330
Alphagan PBrimonidine Tartrate24$5,902
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat333$5,752
Brimonidine Tartrate281$5,450
CombiganBrimonidine Tartrate/Timolol14$5,192
MoxifloxacinMoxifloxacin Hcl175$3,984
Latanoprost403$3,119
Ketorolac Tromethamine90$1,666
Dorzolamide Hcl65$1,304
Acetazolamide ErAcetazolamide24$1,010
Atropine Sulfate14$704
Timolol Maleate45$359
ErythromycinErythromycin Base24$239
Ofloxacin14$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieAlphagan P, Combigan$1,123$11,09438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 150 ophthalmology providers in Mississippi.

Other ophthalmology in Madison

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →